Please upgrade your browser.
In a study published in the journal Science Translational Medicine, the researchers detail how low doses of the drug interleukin-2 (IL-2) can alleviate chronic graft-versus-host disease (GVHD), a debilitating condition that often occurs in patients who have received a stem cell transplant. In patients with chronic GVHD, donor immune cells launch an attack on healthy tissue. IL-2 is so versatile at restoring immune system balance, the researchers found, that it may eventually become a primary treatment for chronic GVHD and may even hold promise for treating autoimmune diseases, such as rheumatoid arthritis and lupus, which result from a misguided immune system attack on otherwise healthy organs and tissues.
Functioning kidney built from newborn rat cells is a major step towards personalised transplant organs for people.
M. D. Anderson annual Kidney Cancer Association Patient & Survivor Conference, Houston, Texas
The nonprofit Association of Cancer Online Resources (www.acor.org) cancer email lists are apparently being abandoned in favor of a new for-profit business model.
New website offers kidney cancer survivors the opportunity to share stories about their cancer journey, while connecting with others on an interactive map of the world.
Renal cell carcinoma (RCC) may involve both kidneys. When bilateral nephrectomy is necessary renal replacement therapy is mandatory. Treating such patients with sequential therapy based on cytokines, antiangiogenic factors and mammalian target of rapamycin (mTOR) inhibitors is challenging.
How does your state rank? Customize the infographic with your criteria.
An experimental drug that spurs the immune system to fight cancer appeared to be safe and demonstrated anti-tumor activity against a variety of cancers in a small early stage study, researchers said on Tuesday.
The engineered antibody MPDL3280A, which targets a protein called programmed death-ligand 1 (PD-L1), was safe and effective for several cancers, according to phase I study results presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10
Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR
Presentations Highlight Preclinical Data for Novel SGN-CD33A and SGN-LIV1A Programs and Breakthroughs in Research to Develop Highly Stable Linkers and More Potent Chemotypes.
|Powered by NeonCRM|